You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Platinum-based therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Small Cell Lung Cancer Recurrent Trial in Madrid, Pamplona, Valencia (Debio 0123, Etoposide, Carboplatin)

Not yet recruiting
  • Small Cell Lung Cancer Recurrent
  • Debio 0123
  • +2 more
  • Madrid, Spain
  • +3 more
Apr 3, 2023

Pancreatic Adenocarcinoma Trial in Philadelphia (Niraparib + Nivolumab, Niraparib + Ipilimumab)

Active, not recruiting
  • Pancreatic Adenocarcinoma
  • Niraparib + Nivolumab
  • Niraparib + Ipilimumab
  • Philadelphia, Pennsylvania
    University of Pennsylvania, Abramson Cancer Center
Mar 23, 2022

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022

NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 17, 2023

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

Locally Advanced, NSCLC Trial in Shanghai (drug, procedure, radiation)

Recruiting
  • Locally Advanced
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Shanghai Pulmonary Hospital
Mar 14, 2023

Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma Trial in Darlinghurst, Kogarah,

Terminated
  • Advanced Solid Tumor
  • +3 more
  • Darlinghurst, New South Wales, Australia
  • +1 more
Dec 18, 2022

Stage III NSCLC Trial (Toripalimab, JS004, Pemetrexed)

Not yet recruiting
  • Stage III Non-small Cell Lung Cancer
  • (no location specified)
Jun 3, 2023

Nivolumab in Germany With Squamous Cell Carcinoma of Head and

Active, not recruiting
  • Head and Neck Cancer
    • Leipzig, Germany
      Local Institution
    Aug 11, 2021

    Advanced or Metastatic NSCLC Trial in Moscow, Saint Petersburg, St. Petersburg (Ceralasertib, Durvalumab)

    Recruiting
    • Advanced or Metastatic NSCLC
    • Moscow, Russian Federation
    • +7 more
    Jul 4, 2023

    A Study of Nivolumab in Patients With Head and Neck Cancer.

    Active, not recruiting
    • Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck
    • Nivolumab
    • Paris Cedex 5, France
      Local Institution
    Mar 23, 2022

    NSCLC Trial (QL1706 injection, Vinorelbine Tartrate, Paclitaxel)

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • QL1706 injection
    • +6 more
    • (no location specified)
    Aug 3, 2022

    Metastatic Cancer, Urothelial Carcinoma Trial (avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin)

    Not yet recruiting
    • Metastatic Cancer
    • Urothelial Carcinoma
    • avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
    • (no location specified)
    Dec 19, 2022

    Non Small Cell Lung Cancer Trial in Changsha (Atezolizumab)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer hospital
    May 19, 2022

    Squamous Cell Carcinoma of Head and Neck Trial in Shanghai (Docetaxel, Nivolumab)

    Recruiting
    • Squamous Cell Carcinoma of Head and Neck
    • Shanghai, Shanghai, China
      Guo Ye
    Jan 27, 2022

    Breast Cancer After Ovarian Cancer During and/or After Therapy:

    Recruiting
    • BRCA-Associated Breast Carcinoma
    • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Mar 9, 2023

    NSCLC, Tumors Trial in Canada, Poland, Romania (Debio 1143, Avelumab)

    Completed
    • Carcinoma, Non-Small-Cell Lung
    • Neoplasms
    • Edmonton, Alberta, Canada
    • +8 more
    May 30, 2022

    NSCLC Metastatic Trial (bevacizumab plus nab-paclitaxel and platinum)

    Not yet recruiting
    • Non-small Cell Lung Cancer Metastatic
    • bevacizumab plus nab-paclitaxel and platinum
    • (no location specified)
    Jun 2, 2022

    Pancreatic Cancer Trial in Philadelphia (RUCAPARIB)

    Active, not recruiting
    • Pancreatic Cancer
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Nov 10, 2021

    Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

    Recruiting
    • Ovarian Cancer
    • +2 more
    • New Orleans, Louisiana
    • +3 more
    Dec 16, 2022

    Ovarian Cancer, Cognitive Impairment Trial (N-Acetyl-Cysteine, Placebo)

    Not yet recruiting
    • Ovarian Cancer
    • Cognitive Impairment
    • (no location specified)
    Sep 30, 2021

    Advanced Urothelial Carcinoma Trial in Boston (copanlisib, Avelumab)

    Not yet recruiting
    • Advanced Urothelial Carcinoma
    • Boston, Massachusetts
      VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain,
    Jan 13, 2023

    PD-1 Blockade Plus Platinum-based Chemotherapy in EGFR Sensitive

    Completed
    • Non Small Cell Lung Cancer
      • Changsha, Hunan, China
        Hunan Cancer Hospital
      Mar 9, 2022